K2 Therapeutics appointed Ying Huang as its new CEO, following his departure as CEO of Legend Biotech. K2 is positioning itself as a drug discovery search and licensing platform, seeking “high-potential” medicines by sourcing prospects from China-based biotechs. Huang’s move signals a continuation of cross-border pipeline harvesting, where leaders with clinical and commercial experience take a more portfolio-orchestration approach rather than building every asset in-house. The startup’s strategy centers on licensing multiple prospects and expanding its pipeline through additional sourcing. For the industry, the CEO transition is notable as it blends execution experience from large cell therapy operations with a search-first model that can accelerate early-stage portfolio formation.